List of Small Molecule Pharmaceuticals Companies in Canada - 108

Founded in 2017, 48Hour Discovery (48HD) has a powerful technology platform for peptide-based drug discovery. We are reducing the cost, time, and risk of developing new therapies with our innovative target screening strategy to quickly identify the best and most promising drug leads.

The Acadian Seaplants Story Established in 1981, Acadian Seaplants is a family-owned business that revolutionized the seaweed industry in Canada and around the world. Over forty years later, Acadian is the world leader in marine plant products for people, animals and plants. With employees in seventeen countries, Acadian is a fully-integrated, biotechnology manufacturer of premium agricultural products for animals and plants, cultivated sea-vegetables and functional ingredients derived from select species of marine plants. The Seaweed Specialists Acadian is an ardent guardian of the marine environment. Decades of research has proven that properly managed, seaweeds are a rapidly renewable marine resource. A pioneer in hand-harvesting technologies that protect the habitat, Acadian is a recognized global leader in the sustainable management of the seaweed resource. Acadian’s products are also eco-efficient, eco-friendly and Acadian is committed to energy efficiency and waste reduction at all stages of manufacturing. Product Excellence Backed by over 40 years of extensive, global scientific research, Acadian products are exported to over 80 countries around the world. Unequalled in science, customer support, and delivering products with proven results, Acadian has two divisions - Acadian Plant Health™ and Human and Animal Wellness™. Both of these divisions have one thing in common – they improve health, productivity and sustainability.

AcuPharma is a Canadian based company that provides a wide range of services for pharmaceutical and biotech partners. Our aim is to assist our clients in reaching their goals by providing chemistry expertise, as well as contract research and custom synthesis.

We apply proprietary computational tools to bacterial metabolomic and genomic data in order to identify, isolate, and assay novel drug-like small molecules in high-throughput to expedite the search for medicines that will better protect us from a wide spectrum of diseases.

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

Alectos Therapeutics is a privately held pharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics for the treatment of human disease. We focus on preclinical drug development, target validation, hit-to-lead optimization, and IND-enabling studies. Alectos develops innovative new strategies to address medical conditions for which there are no effective treatments.

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) is a clinical-stage pharmaceutical development company. Our unique drug repurposing strategy enables us to discover new therapeutic uses for existing drugs. This business model lowers investment, risk, and research periods while increasing active patent life. Twitter: @AlgernonPharma Facebook: @AlgernonPharmaceuticals

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

Ananda Devices is a biotech company providing innovative Neuron-on-a-chip technology. Our high-throughput systems allow our clients to accelerate drug development, toxicity screenings, disease modeling and more. Maintaining the goal of reducing animal testing, our devices allow for 100% human based models while increasing physiological relevance.

Andira Pharmaceuticals is a private healthcare company delivering purposeful innovation to improve lives and address critical illness. We are pioneering a new generation of therapeutics by leveraging the power of natural drug substances to deliver urgently-needed solutions for both consumer and hospital-based medical indications.​ Andira’s lead products address highly prevalent medical indications in three areas: Hospital-Acquired Infection Oncology Dermatology Our groundbreaking technologies originate from a validated pharmacotherapeutic platform – allowing us to uncover pharmacologic synergy between natural drug substances and existing medical treatments. Our discoveries are further optimized through careful pre-clinical research to create new therapies with dramatically improved efficacy and safety.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Aquinox Pharmaceuticals is a biopharmaceutical company that focuses on drug development and conducting clinical trials in the healthcare industry.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

We are a Canada Based Contract Research Organization with expertise in contract research, custom synthesis, analytical services, and drug development. We support all your research needs by reducing the project timeline and cost.

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

AtomVie Global Radiopharma Inc. is a contract development and manufacturing organization (CDMO) based in Hamilton, Ontario, Canada. Established in August 2022, the company specializes in the production of radiopharmaceuticals, focusing on both clinical and commercial applications. AtomVie is recognized for its Good Manufacturing Practice (GMP)-compliant production, drawing on over ten years of expertise from its predecessor, the Centre for Probe Development and Commercialization (CPDC). The company is expanding its capabilities with a new multi-product facility, set to significantly increase production capacity. AtomVie offers a range of services, including GMP manufacturing of radiotherapeutics and medical isotopes, regulatory support with a strong approval track record, and logistics management for the global distribution of short-lived radiopharmaceuticals. AtomVie serves over ten international pharmaceutical companies and supports clinical trials across more than 17 countries, emphasizing reliability in its production and logistics processes.

Attix Pharmaceuticals designs and sellsactive pharmaceutical ingredients and ingredients for nutraceuticals, and food, for both human and veterinary applications.

We pursue promising science to address some of the toughest challenges in autoimmune disease. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. 2. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. 3. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. 4. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: https://www.auriniapharma.com/aurinia-community-guidelines US-NA-2300266 08/23

Aurora Biomed is committed to supporting life science, drug discovery/safety, and chemical analysis research by providing enabling technologies and services which offer higher throughput while maintaining quality, accuracy, and precision. Aurora's product range includes automated liquid-handling workstations, atomic absorption spectrometers, atomic fluorescence spectrometers, microwave digestion systems, and water purification systems.

Biolyse Pharma specializes in manufacturing and developingof sterile oncology drugs.- Currently produces Paclitaxel for the treatment of cancer, known for its mild side effects when compared to similar chemotherapy agents- Supplies 80 per cent of the Canadian demand for Paclitaxel

BioNxt Solutions is a leading bioscience company that rapidly innovates drug formulations, diagnostics, drug delivery, and neurological drugs.

Expertise in both microbial fermentation and chemical synthesis allows us to tackle today's development pipeline's increasingly complex molecules. In fact, we thrive on the vexing challenges few CDMOs would have either the expertise or desire to address. Bold vision, along with the passion and commitment to make that vision reality, is at the heart of our organization. We are a forward-thinking, North American CDMO Pharmaceutical company specializing in clinical-to-commercial scale production capabilities for: Synthetic small molecules Fermented small molecules Highly potent APIs Biologics Bioreagents Flexibility, creativity, and dedication to process optimization are at the heart of our method and process development as well as quality and compliance efforts. We assure the programs advance on time and with the highest quality outcomes under our project managers' leadership.

Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.

Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.

Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. Cardiol has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.

Clearmind Medicine develops novel psychedelic medicines to solve widespread—yet under-served—health problems. With a strong medical management and IP-protected.

Be Clinic Ready! Corealis Pharma provides services on a contract basis in the areas of Formulation & Process Development as well as in small scale Clinical Trial Material (Phase I and II) Manufacturing and the packaging of solid dosage forms (tablets & capsules) to pharmaceutical and biotech companies. Our services include: API characterization; salt selection; pre-formulation; formulation & process development; analytical method development; stability storage & testing; technical transfer and scale-up; cGMP manufacturing & packaging of Phase I and II CTM; dossier support for American, European, and Canadian submissions. Our experts have access to modern well equipped R&D and cGMP manufacturing & packaging facilities that allow them to successfully complete the most challenging and complex mandates. The primary objective of Corealis and its staff is to make every one of their customers succeed. Corealis Pharma Inc. offers personalized and efficient services in the areas of Formulation Development and Clinical Supply Manufacturing of solid oral dosage forms.

Cybin is a biotechnology company that focuses on developing psychedelic therapeutics for mental health treatment.

DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.

Dalton is a contract pharmaceutical manufacturer which provides integrated chemistry, development, and manufacturing to biotechnology and pharmaceutical clients around the world. In its 42,000 sq. ft. facility, Dalton operates - cGMP manufacturing of Active Pharmaceutical Ingredients (APIs), - sterile injectables, - finished drug products in vials or syringes - solid oral dosage forms. APIs can be produced in gram to kilogram quantities, including sterile APIs. Dalton contract capabilities can support you at any stage of the regulatory process (Phase I, II, III, or commercial). Development services include - chemistry and process development, - medicinal chemistry, - custom drug conjugation, - targeted drug delivery systems, - analytical method development and validation, - ICH stability testing, - formulation, and - polymorphism screening. Dalton also supports the industry's pharmaceutical research programs with a catalog of 2,500 reference standards, building blocks, metabolites, and impurities with its Dalton Research Molecules division.

VAL-083 is a small-molecule chemotherapeutic that benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved as a cancer therapy overseas. Efficacy has been demonstrated in a range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Del Mar Pharma has filed an IND with the USFDA to initiate a dose-escalating Phase II clinical trial in refractory GBM, a major market opportunity.

Derm-Biome Pharmaceuticals, Inc. is a Vancouver-based preclinical biopharmaceutical company founded in 2018 focused on developing and advancing safe and effective topical therapies for inflammatory skin disease, acne, and other skin conditions. The company is also involved in research related to skin cancer and healthy aging.

Dionamix Scientific Inc. is a rapidly evolving company boasting over a decade of expertise in chemical analytical instruments such as an All-In-One Solution for Lipid Nanoparticle Synethsization, HPLC, UV-Vis Spectrometer, Diode Array Detector, Autosampler, and Chromatography Workstation Analytical Software. Specializing in designing and manufacturing IP-rich chromatography and spectroscopy analytical instruments, Dionamix Scientific has a proven track record of over 10 years in delivering innovative products. Our mission is to provide tailored solutions for analytical lab managers, as well as quality and safety-focused professionals in the food, beverage, and natural medicine industries, offering efficient and cost-effective compound analysis. With a global team dedicated to innovation, quality, and exceptional customer service, we strive to optimize solutions for small to medium-scale operations. While you focus on your product, Dionamix specializes in sample separation and analysis, collaborating to unveil crucial details determining the concentrations, quality, and safety of your produce. has context menu

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

ESSA’s initial focus is in the treatment of prostate cancer. Prostate cancer is a male hormone (androgen) driven malignancy, and six decades of drug development have resulted in continuous improvements in anti-androgen therapy. Yet resistance commonly develops to drugs. ESSA had developed a new class of drugs, the “anitens”. These drugs interrupt androgen-driven biology in a novel manner and are active even in the setting of resistance to current anti-androgen therapies.

Everest Clinical Research ("Everest"​) is a full-service contract research organization (CRO) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. We serve some of the best-known companies and work with many of the most advanced drugs, biologics, and medical devices in development today. Everest has been an independent CRO since 2004 with a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with headquarters located in Markham, Ontario, Canada, with additional offices in Little Falls (Greater New York City Area), New Jersey, USA, and Shanghai, China. Everest is known in the industry for its high quality deliverables, superior customer service, and flexibility in meeting clients' needs. A dynamic organization with an entrepreneurial origin, Everest continues to experience exceptional growth and great success Quality is our backbone, customer-focus is our tradition, flexibility is our strength...that's us…that's Everest! Important Information for job candidates: Please be aware of cyber-security due to some fraudulent job scams. Everest will follow our standard and thorough recruitment process which will include video panel interviews: https://www.ecrscorp.com/recruitment-process/ Everest email communication will come from an ecrscorp.com email address. Emails from other domains may not be from Everest. Everest will never ask for credit card information or charge fees at any time during the recruitment process. If something is portrayed as Everest but does not appear to be from Everest, please feel free to contact us at https://www.ecrscorp.com/contact/

Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial drug candidates that will address the challenge of antimicrobial resistance (AMR). Fedora is interested in exploring partnerships and/or licensing agreements with industry and academia to support its growing pipeline of product candidates. For more information on business development opportunities at Fedora, please contact Fedora at info@fedorapharma.com.

We develop clinically driven, first-in-class, tissue-specific therapeutics from human diseased tissue to treat specific fibrotic disease populations.

We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases. Dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases, our company was launched in 2020 with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and an exclusive global license from Strasbourg University on a technology and related know-how initially developed by Dr. Dominique Bagnard.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.

Acasti Pharma Inc. (ACST) is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company's novel drug delivery technology platforms provide a versatile and flexible capability to develop and manufacture a wide range of pharmaceutical dosage forms, including oral, injectable, and topical, as well as various products to treat rare and orphan diseases. Acasti's lead product candidate is CaPre, an omega-3 phospholipid therapeutic for the treatment of severe hypertriglyceridemia, a condition that affects an estimated one third of the U.S. population. The Company is also developing a medical food, Onemia, for the treatment of patients with hypertriglyceridemia. Acasti Pharma is headquartered in Laval, Quebec, Canada.

Clinical Development Solutions (CDS) is a Contract Research Organization providing strategic drug development, clinical trial, regulatory, pharmacovigilance and quality assurance consulting to biotechnology, pharmaceutical and medical device companies. CDS understands the unique needs of small companies. With our North American regulatory expertise, we can add value and efficiency to your clinical trials and FDA and Health Canada interactions. Our strategies will help you get proof of concept established earlier and new products and indications to market faster. CDS offers complete clinical trial management services in Canada and the US including site selection, monitoring, quality assurance, project management and post-market pharmacovigilance. CDS will be a valuable collaborator with your emerging life science or medical device company.

Pioneering next-gen precision therapeutics for diseases stemming from microtubule dysfunction, such as neuropathies and cardiovascular diseases.

The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. Who We Are HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), Dorval (Montreal, Quebec), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug’s originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada’s regulations. Our Goal/Our Mission HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.

IBEX is a pharmaceutical company that specializes in manufacturing and selling high purity enzymes for in-vitro diagnostics and research, as well as osteoarthritis kits for pre-clinical research.

IFOWONCO uses advanced computational modelling techniques coupled with state of the art machine learning to rapidly identify and optimize drug candidates.

Science has successfully shown that the human immune system can be enhanced by introducing immunoglobulin or Ig antibodies targeted toward specific pathogens. The highest concentration of compatible Ig is found in chicken hen eggs called IgY. Our proprietary ability to commercially produce IgY antibodies presents the breakthrough potential to solve some of the most important immune health challenges faced today. Our proprietary technology and process allows for the most cost-effective highest purity IgY protein antibodies globally available today with purity levels up to 95% . Our IgY is 100% natural with no harsh chemicals used in the extraction process, a low flavor, odor & color profile and is available in powder & liquid format making it attractive for a variety of applications including nutraceuticals such as general dietary daily supplements from infants to seniors, General foods & beverages, Sports nutrition supplements, Pet food & health products. There are also cosmeceutical, agricultural and pharmaceutical applications.

ImmVue Therapeutics is a company that develops small-molecule screen KISMEHT to identify allosteric modulators of the kinase family. Its lead compounds use lymphocytes and aim to revert patients to their vibrant selves with innovative medicines that target novel mechanisms to revitalize their immune system.

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Nasdaq: INM

Acquired by Novo Nordisk in 2023. Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy, Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

ITR Canada provides preclinical testing services for the pharmaceutical and biotechnology industries. Since our founding in 1989 we have grown into a mid-sized Contract Research Organization (CRO). As a CRO with extensive experience, we provide you with valuable input and best practices, which ultimately help you maximize the value of your research investment. We deliver on time project reporting that meets your company's goals. ITR Canada offre des services d'essais précliniques pour les industries pharmaceutiques et de biotechnologie. Depuis notre création en 1989, nous nous sommes développée en une organisation de recherche contractuelle (CRO) de taille moyenne grandissante. En tant que CRO avec une vaste expérience, nous vous fournissons une contribution valable et les meilleures pratiques disponibles, qui vous aident finalement à optimiser la valeur de votre investissement en recherche. Nous vous livrons des rapports de projet en temps voulu et qui répondent aux objectifs de votre entreprise.

Juno Pharmaceuticals Canada sources, develops, and delivers life saving specialized pharmaceutical products for Canadian patients. Our colleagues work with trusted partners to co-develop novel drug delivery mechanisms that satisfy untapped market demand, first to market generic products, biosimilar offerings, and patent challenge strategies. Juno's portfolio consists of both branded and generic drug assets in multiple presentation forms including injectable drugs (vials, amps, & pre filled syringes), complex biosimilars, ophthalmic products, oral does tablets and capsules, prescription dermatology topicals, and other unique dosage systems. Our team have deep roots into the Canadian hospital space, retail pharmacy market, specialty channels, and a robust B2B platform. In addition, Juno Canada has recently embarked with product sourcing in the animal health space and remain focused on opening new delivery channels and customer groups to facilitate supply for Canadian patients. Juno is proud to supply 5 molecules deemed medically necessary by the World Health Organization on their critically essential medications list, and we are actively pursuing export opportunities to countries in need of our critical medications. To learn more about Juno Pharmaceuticals Canada please contact us at communications@junopharm.com For sales enquiries contact us at sales@junopharm.com

Knight Therapeutics Inc. (TSX:GUD) is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and select international markets.

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Life Chemicals Inc. Niagara-on-the-Lake, Canada, specializes in state-of-the-art organic synthesis for high-throughput screening: - Drug-like and lead-like screening compounds; - Carefully designed targeted libraries; - Building blocks and intermediates; - Custom synthesis projects. As an advanced synthetic laboratory Life Chemicals employs the high skills and research abilities of more than 80 qualified professionals. It also takes advantage of its co-operation with 14 leading Universities, Academic and industrial laboratories and is the largest exporter of their HTS compounds. Life Chemicals operates worldwide and in addition to its main office in Niagara-on-the-Lake, Canada, it has a US office in Orange, CT, and a European office in Munich, Germany. The production site is located in Kyiv, Ukraine. The Company sells its products and services to more than 1000 customers, with its sales volume steadily growing. Keeping pace with market demands, Life Chemicals does offer mutually beneficial terms and very competitive prices, thus making the ratio of product quality and its cost most attractive for our customers.

Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing promising research in small molecules for a range of diseases related to fibrosis including respiratory, liver and renal diseases. Through a separate business unit called Prometic, the company also focuses on the use of bioseparation technologies to isolate and purify biopharmaceuticals derived from human plasma.

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and distribution of pharmaceutical products. The company has completed the acquisition of Virage Santé and has entered into an exclusive distribution agreement with Fera Pharmaceuticals to alleviate drug shortage in U.S. hospitals. LSL Pharma Group Inc. is listed on the TSX Venture Exchange under the ticker symbol LSL.V.

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to address hypertriglyceridemia and other metabolic diseases.

Marvel Biosciences is an agile, Calgary-based biotechnology company revolutionizing drug development by de-risking the (re)development of existing drugs to create novel therapeutics with enhanced efficacy and safety profiles. We capitalize on modifying known, off-patent drugs to deliver faster, safer, and more effective treatments. Our streamlined approach significantly reduces development costs, shortens timelines, and lowers risk compared to traditional biotech models. Our lead compound has shown remarkable promise in preclinical studies, demonstrating efficacy for a wide range of conditions, including depression, anxiety, Alzheimer's disease, and autism. We are also actively investigating its potential in addressing other genetic disorders, such as Rett syndrome and Fragile X syndrome, further expanding our therapeutic reach. We have completed cGMP synthesis, toxicology studies, and preparation for Phase 1 clinical trials and are well-positioned to bring our groundbreaking solutions to market.

Mati Therapeutics is a healthcare company that specializes in developing a proprietary ophthalmic drug delivery system using punctal plugs for introducing therapeutic agents.

Mesentech is a clinical stage biotechnology company developing novel medicines that selectively distribute to the intended site of action. MES1022 is a clinical stage program for bone-repair being developed for 3 indications. Our preclinical pipeline includes novel compounds targeting bone-cancers.

Metabolica Health Inc. is a development stage biotechnology firm discovering and developing innovative treatments for diabetes and obesity.

ME Therapeutics is a Biotechnology company that specializes in Immuno Oncology, focusing on treating previously untreatable cancers by targeting the immune system.

Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States.

Our proprietary technology focus on the dual functions of pentamidine on controlling the function of a DNA repair enzyme – endo-exonuclease (EE:Trmt2) and specific targets anti-inflammatory/Lipopolysaccharide (LPS) binding. The EE is found in large amounts in cancer cells and its function is to repair DNA breaks that occur when cancer cells proliferate. Blocking this enzyme would cut off cancer growth. With a unique combination of proprietary expertise on EE (Trmt2) and pentamidine, the company is well positioned to develop pentamidine analogs for breakthrough solutions in cancer therapy1-5. Pentamidine is known to be active on cancer cells. The effectiveness and significance of DNA repair process in medicine has most recently been exemplified in 2015 Nobel Prize in Chemistry. The effect of pentamidine as potential anti-inflammatory agent is well documented6,7. However, its development for anti-inflammation application is limited by its cytotoxic effect. With proprietary technology, we are able to identify pentamidine analogs that retains the anti-inflammation activity but reduce cytotoxicity to broaden our scope into Gastro-intestine (GI) condition as well as liver disease.

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development is currently being performed.

Naegis Pharmaceuticals is an ophthalmology-focused biopharmaceutical company developing new oral and topical therapies, active in the discovery and development of novel small molecules that target underlying chronic inflammatory processes in eye diseases.

RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique d'une nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.

Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases.

Noa Therapeutics is a preclinical biotech company pioneering the development of multimodal therapies. Singular, non-steroidal, small molecules with tunable therapeutic drivers are offered to address complex immune diseases, enabling patients to achieve better outcomes.

Nutrasource is a full-service contract research organization (CRO) that helps health companies bring products to market with strong science and regulatory confidence - from concept to claim. Through our vertically-integrated service platform, Nutrasource is your one-stop shop for international regulatory, clinical, and product testing solutions for dietary supplements, pharmaceuticals, and everything in between. As your virtual R&D department, we will help you tackle your toughest scientific problems so you can sell safe, effective, high-quality products to improve healthcare globally. Originally established as a diagnostic test provider nearly two decades ago, Nutrasource has since grown from a single desk to a global CRO employing over 100 staff across four sites in North America. By focusing first and foremost on the needs of our customers, we are proud to have helped hundreds of clients develop, launch, and market health products across the globe.

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

Optimi Health exists to grow psychedelic science and medicine as an industry-leading supplier of natural, pharmaceutical-grade psilocybin and synthetic psychedelic compounds. Our Purpose is to produce scalable, natural mushroom formulations and other psychedelics for transformational human experiences. Our Goal is to be the number one trusted, compassionate supplier of safe, natural EU-GMP-grade psilocybin and synthetic psychedelics across the world. Our Promise is to make possible a future whereby psychedelic alternatives aid a wide variety of mental health conditions.

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.

Pan-Biome Pharmaceuticals, Inc, is a Vancouver-based preclinical biopharmaceutical company spun out two years ago with a focus on developing safe and highly effective drugs to promote healthy aging and healthspan. We recently developed a new generation of natural product-based small molecule compounds that exhibit a variety of beneficial biological activities with the potential to modulate important pathways that, when altered, can lead to the development of inflammatory, immune and degenerative diseases.

Pharma Inventor Inc. is a Canadian Chemistry R&D and Analytical Services company established to serve the needs of pharmaceutical, biotech and agrochemical industries as well as research institutes/academic research groups in North America to support their innovative R&D/Analytical testing activities. Reach out to us for Custom Organic Synthesis / Medicinal Chemistry / Analytical Services / Process Chemistry Works / IP Consultation.

PharmAla Biotech Inc. is a Canadian Biotechnology company dedicated to the research, development, manufacture and sales of MDMA in service to the clinical research community.

Pholoho Biotechnology, established in 2019 in Canada, specializes in agricultural and nutraceutical biotechnology. The company develops products based on microalgae strains, designed for the prevention, management, and treatment of malnutrition and various human diseases.

Patients need reliable FDA approved cannabinoid treatments. Developing safe and effective cannabinoid formulations with superior drug delivery is our answer.

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer. On Dec. 27, 2023, Lilly Completes Acquisition of POINT Biopharma.

Psyence (PSYG) is a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well‑being. We have a focus on these conditions in the context of palliative care. Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com

QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCan's next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.

Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on a novel series of small-molecule DNA-damage response inhibitors. The company focuses on utilizing Deep Docking™ AI to target DNA-damage response (DDR) for oncology-focused treatments. Their target markets include breast cancer, ovarian cancer, and prostate cancer.

We are a Canadian publicly traded Canadian life-sciences company that provides innovation, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers quick, convenient precise and discreet™ and smoke-free choices to consumers. RDT is focused on clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to innovative solutions for future market needs — including humans, animals and plants. We are now publicly listed on the Canadian Securities Exchange: $DOSE.

Regulatory Heights is a regulatory consulting company that offers quality, clinical, pharmacovigilance, and medical information consulting services to corporations in the medical and consumer product supply chain.

Replicor Inc. is a Canadian biotechnology company focused on the development of its nucleic acid polymer (NAP) technology for the treatment of hepatitis B (HBV) and delta (HDV) infections. NAPs are the only antiviral agent to directly target the immunosuppressive protein (HBsAg) which drives chronic HBV infection and liver disease. Our lead clinical NAP drug product is REP 2139-Mg, a proprietary formulation of REP 2139 which makes once weekly subcutaneous injections easily tolerated. Replicor's latest clinical data demonstrates that NAP-based combination therapy can restore immune control of HBV infection in 78% of patients and eliminate HDV infection in 74% of patients. These effects persist in the absence of any therapy, allowing the liver to heal. REP 2139-Mg based combination promises to revolutionize the therapy of chronic HBV and HDV infection and play a pivotal role in the WHO's goal of eliminating viral hepatitis by 2030.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.0

Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.

Satisfai Health is on a mission to create the most comprehensive AI solution for gastrointestinal (GI) practice and research. To realize this vision, we aim to enhance the quality, speed, and affordability of existing methods for the detection, diagnosis, assessment and treatment of disease. Satisfai Health's AI products cover a range of applications in Upper and Lower GI, delivering innovative measurement, tracking and reporting on the most important clinical findings. Our core focus is enhancing human experiences. Through technology, we deliver personalized and precise approaches that benefit both caregivers and patients. Our solutions are used by pharmaceutical companies and contract research organizations in the drug development process, and will be used by practicing GI physicians in clinical practice. Our team is composed of highly experienced physicians, data scientists, software engineers and healthcare business professionals. We work with a network of globally recognized scientific and clinical experts, and are fortunate to be supported by some of the world's leading venture capital and private equity groups. We are growing quickly and always looking to add high quality talent in the right areas.

SignalChem Lifesciences - Headquartered in British Columbia, Canada, SignalChem was established in 2004 and became a global leader in cell signaling and protein engineering. The company employs 60 scientists and consists of four business units. SignalChem’s Bioreagent unit generates worldwide, annual sales expected to reach ~$8M this year. This unit’s success has enabled the Drug Discovery unit to remain non-diluted and self-funded. The Drug Discovery unit includes five projects in various stages of development benefiting from the company’s core expertise and knowledge. SLC-391 (a potent and selective AXL inhibitor) is its most advanced program in late-Phase I clinical development. SignalChem is now entering its first-ever round of financing, seeking $20M to complete Phase II clinical development in oncology, which is planned to start in Q1, 2022. SignalChem is open to a variety of business/financial models to support our efforts to bring SLC-391 to patients suffering from Cancer. To learn more about SLC-391, join us for a partnering meeting or attend our conference presentation. We look forward to meeting you.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem (located in France) is the recipient of multiple French scientific awards and European Union and French government grants. Sirona Biochem is a publicly-traded company. The company is listed on the TSX Venture Exchange in Canada under the symbol SBM, the OTC Pink Sheets in the United States under the symbol SRBCF and in Frankfurt under the symbol ZSB.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental illness, neurological and pain disorders.

SYNG Pharmaceuticals Inc. (SYNG Pharma) is a pre-clinical stage biotechnology company dedicated to developing next generation diagnostic and therapeutic against endometriosis. The company is developing a novel peptide, SP011, to inhibit a target now known for its role in the proliferation of cells. SYNG Pharma has a potential to develop a treatment that would be a much needed alternative to currently available, partly ineffective, hormonal therapy. There are many other potential applications of SYNG Pharma technology including the treatment of fibroids and uterine sarcoma; breast and prostate cancer which may be further developed depending upon corporate interests and an opportunity for partnership.

Synucure Therapeutics inc. is a Canadian biotechnology company conducting research in brain degenerative disorders. Synucure was founded in 2021 with the key objective to pursue the promising and robust pre-clinical work of Dr. Francesca Cicchetti on a repurposed drug called Cysteamine which demonstrated, in various animal and cell models, that the drug could prevent and/or reverse a number of features related to Parkinson’s Disease (PD). Her research on the potential benefits of Cysteamine in neurodegenerative disorders was initiated 20 years ago. In addition to the promising role of Cysteamine as a Disease Modifying Therapy (DMT) in Parkinson, Dr. Cicchetti and her colleagues conducted research on patented blood biomarkers, of which the main objective is to provide clinicians with a more precise diagnostic and stratification tool for the disease using a simple blood test. If you need more information, please contact us at info@synucure.com

Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. The company currently markets two medicines in HIV and has research programs in HIV, NASH, and Oncology.

Translatum Medicus Inc is a preclinical drug development company focused on macrophage modulation to treat blinding eye disease, with a patented lead drug candidate, TMi-018 for the treatment of dry Age-Related Macular Degeneration (AMD). Translatum is based in the Johnson & Johnson Innovation Incubator JLABS@Toronto, and has been increasingly gaining traction as one of the most innovative early stage ophthalmic biotech companies.

uFluidix specializes in manufacturing silicone (PDMS) and thermoplastic (PMMA, PC, PS, COC, and COP) microfluidic chips and devices for microtechnology applications. Our expertise in the development and processing of these micro-featured components goes beyond the know-how of most of the plastic industry, who use conventional molding, stamping or rolling technologies. Our two differentiators are: 1. We affordably fabricate plastic parts with features accurate within +/- 0.5um if needed. 2. We bond or laminate hard-to-bond parts with less than 1% distortion of their sensitive micro-features. Over 10 years of experience has rewarded uFluidix with knowledge proven to be useful for a wide range of applications. If you are currently conceptualizing, improving, or validating an application from the list below we invite you to a friendly chat with one of our development specialists. We ensure you would hear something from us that is worth the experience. Applications: • Point-of-Care Blood/Urine Analysis Cartridges • Complicated Micro Arrays • Tissue Engineering Scaffolds • Customized Cell Culture Systems • Opto-electrical Methods • Point-of-Care Biomarker Detection • Pathogen Detection in Human/Animal • Optical-MEMS • Toxicity Measurements in Droplet Samples • Drug Efficacy Monitoring in Tiny Body Fluids • Cell Separation • Benchtop Cell Count Measurement • Fluidic Drug Delivery • Cancer Research via Biomarker or Cell Analysis • In-Vitro Platforms for Stem Cell Research • Selective Methods for Fertility Aid • Microfluidic Systems • Point-of-Care Sequencing Solutions • Portable Forensic Devices https://www.ufluidix.com/microfluidics-applications/ Any questions? Please visit ufluidix.com or email us at info@ufluidix.com

Verity Pharmaceuticals is a specialty pharmaceutical company that focuses on commercializing therapeutically relevant prescription medicines that are in short supply or absent from the Canadian health care environment. Verity Pharmaceuticals is managed by experienced pharmaceutical executives and guided by a globally recognized scientific advisory board.

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.

XORTX Therapeutics Inc. is a late stage clinical pharmaceutical company dedicated to developing new therapies for progressive kidney disease. The company has two clinically advanced products in development, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XORTX Therapeutics Inc. is also focused on developing innovative therapies to treat progressive kidney disease, with three drug development programs, two of which are clinically advanced products under development.

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life..